CareDx, Inc. (CDNA) News
Follow CareDx, Inc. (CDNA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 21 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
CareDx Raises 2026 Revenue and Adjusted EBITDA Guidance
CareDx raised its 2026 revenue guidance to $520 million-$530 million and adjusted EBITDA guidance to $90 million-$100 million.
EARNINGS | Oct 29, 2026, 08:24 PM UTC
M
CareDx Reports Third-Quarter Revenue of $139.4 Million
EQUITY | Oct 29, 2026, 08:15 PM UTC
M
CareDx Reports Third-Quarter 2026 Financial Results
CareDx reported results for the quarter ended September 30, 2026. The supplied excerpt does not include financial figures.
EQUITY | Oct 29, 2026, 08:02 PM UTC
L
CareDx reports third-quarter net income of $19.3 million
EARNINGS | Oct 29, 2026, 08:01 PM UTC
L
Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY
WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on September 24, 2026, driven by key catalysts such as reaching certain regulatory milestones or results from clinical trials.CareDx Inc. (CDNA)C
NEWS | Sep 25, 2026, 08:54 AM UTC
L
CareDx Price Target Raised to $74.00/Share From $60.00 by BTIG
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 10:21 AM UTC
L
CareDx PT set at $65 by Canaccord Genuity
CareDx has a $65.00/share price target announced by Canaccord Genuity, with an initiation at Buy reported by Benzinga.
EQUITY | Sep 02, 2026, 03:50 PM UTC
H
CDNA Price Target Raised To $60
CDNA price target raised
EQUITY | Aug 06, 2026, 09:44 AM UTC
H
CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 600 points on Monday. Shares of CNH Industrial NV (NYSE: CNH ) rose sharply during Monday’s session after the company reported better-than-expected second-
EARNINGS | Aug 03, 2026, 02:00 PM UTC
H
Stocks Rise After Upgrades, Initiations
Select stocks gain after upgrades and initiations
EQUITY | Aug 03, 2026, 11:52 AM UTC
H
CDNA Upgraded to Buy at Craig-Hallum
CDNA upgraded to Buy with $64 price target
EQUITY | Aug 03, 2026, 11:48 AM UTC
H
AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1
AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:34 PM UTC
H
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after resu
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:18 PM UTC
H
COHU +20%, CDNA +7.2%, MPWR +7.9%, AMZN +6.1% after results
COHU +20%, CDNA +7.2%, MPWR +7.9%, AMZN +6.1% after results
EARNINGS | Jul 30, 2026, 08:04 PM UTC
L
CareDx Raises FY2026 Sales Guidance from $447.000M-$465.000M to $490.000M-$500.000M vs $455.924M Est
CareDx (NASDAQ: CDNA ) raises FY2026 sales outlook from $447.000 million-$465.000 million to $490.000 million-$500.000 million vs $455.924 million estimate.
EARNINGS | Jul 30, 2026, 08:02 PM UTC
L
CDNA Caredx RESULTS: Q2, Q2 ADJ Net Income $20M, Q2 Net Income $111M, Q2 ADJ EBITDA $25M, Q2 ADJ EPS $0.37 vs. EST $0.23, Q2 REV $132M vs. E
CDNA Caredx RESULTS: Q2, Q2 ADJ Net Income $20M, Q2 Net Income $111M, Q2 ADJ EBITDA $25M, Q2 ADJ EPS $0.37 vs. EST $0.23, Q2 REV $132M vs. EST $114M
EARNINGS | Jul 30, 2026, 08:01 PM UTC
L
CDNA Favorable Final LCD for Solid Organ Transplant Molecular Testing; Reiterate Neutral @ HCW
CDNA Favorable Final LCD for Solid Organ Transplant Molecular Testing; Reiterate Neutral @ HCW
EQUITY | Jul 17, 2026, 12:53 PM UTC
L
CDNA PT raised from $28 to $45, maintains Buy @ BTIG
CDNA PT raised from $28 to $45, maintains Buy @ BTIG
EQUITY | Jul 16, 2026, 05:13 PM UTC
H
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Nasdaq Composite falling around 150 points on Thursday. Shares of Abbott Laboratories (NYSE: ABT ) rose sharply after the company reported better-than-expected second-quarter financial re
EARNINGS | Jul 16, 2026, 02:11 PM UTC
L
CDNA Caredx - finalizes medicare local coverage determination for solid organ transplant Molecular testing - Final policy affirms coverage f
CDNA Caredx - finalizes medicare local coverage determination for solid organ transplant Molecular testing - Final policy affirms coverage for Caredx kidney, heart, and lung transplant surveillance - Final lcd published
EQUITY | Jul 16, 2026, 12:33 PM UTC
L
CareDx Completes Sale Of Its Lab Products Operations To Eurobio Scientific For $171.2M
CareDx, Inc. (Nasdaq: CDNA ) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for
EQUITY | Jun 30, 2026, 08:09 PM UTC